Details of Host Protein-DME Interaction (HOSPPI)

General Information of Drug-Metabolizing Enzyme (DME ID: DME1294)
DME Name Rifampicin monooxygenase (rox), Nocardia farcinica DME Info
UniProt ID
ROX_NOCFA
EC Number    EC: 1.14.13.-     (Click to Show/Hide the Complete EC Tree)
Oxidoreductase
Oxygen paired donor oxidoreductase
NADH/NADPH donor oxidoreductase
EC: 1.14.13.-
Lineage    Species: Nocardia farcinica     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Bacteria
Phylum: Actinobacteria
Class: Actinobacteria
Order: Corynebacteriales
Family: Nocardiaceae
Genus: Nocardia
Species: Nocardia farcinica
Interactome
Disease Specific Interactions between Host Protein and DME (HOSPPI)
      Drug co-metabolism
               Cometabolized drug: Rifampicin Click to Show/Hide the Full List of HOSPPI:        7 HOSPPI
                            Cytochrome P450 1A2 (CYP1A2) Click to Show/Hide the Cometabolization Info
DME ID DME0003 DME Info
Uniprot ID
CP1A2_HUMAN
Interaction Name CYP1A2-rox interaction [1], [2]
Description The interaction, between human Cytochrome P450 1A2 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 2B6 (CYP2B6) Click to Show/Hide the Cometabolization Info
DME ID DME0020 DME Info
Uniprot ID
CP2B6_HUMAN
Interaction Name CYP2B6-rox interaction [1], [3]
Description The interaction, between human Cytochrome P450 2B6 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 2C9 (CYP2C9) Click to Show/Hide the Cometabolization Info
DME ID DME0019 DME Info
Uniprot ID
CP2C9_HUMAN
Interaction Name CYP2C9-rox interaction [1], [4]
Description The interaction, between human Cytochrome P450 2C9 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 2D6 (CYP2D6) Click to Show/Hide the Cometabolization Info
DME ID DME0009 DME Info
Uniprot ID
CP2D6_HUMAN
Interaction Name CYP2D6-rox interaction [1], [5]
Description The interaction, between human Cytochrome P450 2D6 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 2E1 (CYP2E1) Click to Show/Hide the Cometabolization Info
DME ID DME0013 DME Info
Uniprot ID
CP2E1_HUMAN
Interaction Name CYP2E1-rox interaction [1], [6]
Description The interaction, between human Cytochrome P450 2E1 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Cytochrome P450 3A4 (CYP3A4) Click to Show/Hide the Cometabolization Info
DME ID DME0001 DME Info
Uniprot ID
CP3A4_HUMAN
Interaction Name CYP3A4-rox interaction [1], [7]
Description The interaction, between human Cytochrome P450 3A4 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Mephenytoin 4-hydroxylase (CYP2C19) Click to Show/Hide the Cometabolization Info
DME ID DME0021 DME Info
Uniprot ID
CP2CJ_HUMAN
Interaction Name CYP2C19-rox interaction [1], [8]
Description The interaction, between human Mephenytoin 4-hydroxylase and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
References
1 Mechanism of rifampicin inactivation in Nocardia farcinica. PLoS One. 2016 Oct 5;11(10):e0162578.
2 Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
3 Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006 Jul;80(1):75-84.
4 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
5 Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab Dispos. 2010 Apr;38(4):679-86.
6 Protective effect of rifampicin against acute liver injury induced by carbon tetrachloride in mice. Jpn J Pharmacol. 1995 Dec;69(4):325-34.
7 Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol. 2010 Aug;50(8):951-9.
8 Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.